Other

Adelaide Research & Innovation Pty Ltd

Gpn Vaccines Pty Ltd

Sungkyunkwan University

Griffith University

The University of Adelaide

Sibtech, Inc.

Adelaide Research and Innovation

James Cleland Paton

Michael Paul Jennings

Marina V Backer

Joseph M Backer

Abiodun David Ogunniyi

Adrienne Webster Paton

Rachelle Babb

Mohammed Alsharifi

Austen Yannis Chen

Shannon Christa David

Timothy Raymond Hirst

Timothy John Mitchell

Hyeok-Young Kwon

David John Hansman

Graham John Boulnois

Peter William Andrew

John Arthur Walker

Adrienne W Paton

Renato Morona

Mu-Hyeon Choi

Christopher Day

Dong-Kwon Rhee

A mutant subtilase cytotoxin B subunit protein is provided which can bind glycans having &#x3b1;2-3-linked N-glycolylneuraminic acid and glycans having &#x3b1;2-6-linked N-glycolylneuraminic acid. The mutant SubB protein has deletions of one or more of the amino acid sequence TTSTE and has a previously undescribed ability to bind glycans having &#x3b1;2-6-linked N-glycolylneuraminic acid, while not losing the ability to bind glycans having &#x3b1;2-3-linked N-glycolylneuraminic acid.

Subtilase cytotoxin B subunit mutant

The present invention relates to photon-irradiated streptococcal vaccine preparations and methods for their use.

Streptococcal vaccine

A method for immunizing a human or animal against pneumococcal infections, comprising by administering a vaccine comprising a purified recombinant caseinolytic protease P (ClpP) protein ofin an immunologically effective amount to the human or animal.

[object Object]

A member of a new class of bacterial toxin has been isolated and characterised. The bacterial toxin is of the ABtype and is characterised in that it has a subtilase domain. It is cytotoxic to Vero cells, and toxicity in vivo in mice occurs in a number of different sites. Mutation of the serine active residue results in greater than 99% reduction in activity. The protein has been purified and antibodies have been prepared for both the A subunit and B subunits, and ELISA detection methods have been developed. The nucleic acid sequence has been determined and primers specific for the toxin have been used for a preliminary screen of a range of patient samples to ascertain the extent to which the toxin is present.

Cytotoxin with a subtilase domain

Chimeric carbohydrates produced by recombinant microorganism carrying exogenous glycosyltransferases act with or without exogenous enzymes required for synthesis or nucleotide synthesis precursors. These recombinant microorganism can be used for competitively inhibiting the binding of toxins or adhesins to receptors of mucosal surfaces, especially gastrointestinal surface. In particular chimeric sugar moieties have been made for lipopolysaccharides, in recombinant microorganism that present multiple copies of the oligosaccharides. The oligosaccharide moieties so presented act as receptor mimic for toxins and adhesins. A number have been synthesized and have been shown to confer protection against attack by pathogenic organisms or their products in vitro and in vivo.

Recombinant microorganisms expressing an oligosaccharide receptor mimic

Mutants of pneumolysin that are non-toxic by reason of amino acid substitutions have been constructed. These mutants elicit an immune response in animals that is reactive to wild-type pneumolysin. The invention also encompasses vaccines for humans based on these mutants, including vaccines comprising conjugates with pneumococcal capsular polysaccharides.

Pneumolysin mutants and pneumococcal vaccines made therefrom

Growing community of inventors

Parkside, Australia

James Cleland Paton